B. Riley analyst Yuan Zhi reiterates a Buy rating on Hyperfine (HYPR) with a $1 price target after the company’s premium Swoop received FDA 510k approval weeks ahead of schedule. The new next-generation MRI system includes a new scanner and Optive artificial intelligence software, producing the highest level of image quality and uniformity, the analyst tells investors in a research note. The firm says Hyperfine kept the hardware development confidential up until yesterday, so it is likely not on many investor radars. Riley points out the trading volume of Hyperfine on Monday was greater than 100M shares, more than the entire float. This trading abnormality could be related to trading algorithms catching the keyword “AI,” the firm contends.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HYPR:
